Celsis Receives Frost & Sullivan 2008 Best Practices Award

Wednesday, October 1, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CHICAGO, Oct. 1 Celsis Rapid Detection, a division ofCelsis International plc (LSE: CEL.L), has been named the Frost & Sullivan2008 North American Growth Strategy Leadership Award recipient for RapidMicrobial Testing Methods used in the Manufacture and Release ofPharmaceuticals.

"The Celsis Rapid Detection system is a powerful and flexible technologythat enables pharmaceutical companies to significantly reduce production cycletimes in the manufacturing process," said Madhu Sharma, Ph.D, industry analystfor Frost & Sullivan. "Not only does Celsis help customers get safe productsto market faster, it returns bottom-line benefits like freed-up workingcapital while reducing inventory and safety stock requirements."

Conventional screening for microbial contamination in raw materials,in-process work or finished goods takes an average of five days at each step.Through the use of a proprietary enzyme accelerant, the Celsis system deliversan accurate verdict in as little as 18 hours, allowing companies to run leanerand more responsive manufacturing systems.

"We are very pleased to be recognized for our leadership in rapid testingmethods for pharmaceutical manufacturers," explained Jay LeCoque, Celsis CEO."Our customers are strong advocates of rapid methods because of the highlyreliable Celsis system, our world-class service, and the simple fact that wesave them significant time and money by taking days out of their manufacturingcycle times."

Frost & Sullivan selected Celsis as a Best Practices Award recipient inthe 2008 North American Growth Strategy Leadership category for the company'sfocused efforts in product innovation, sales strategy, and customer support.The research and growth consulting firm also recognized Celsis' ability toincrease the market presence, regulatory acceptance, and widespread adoptionof its Celsis Rapid Detection systems.

Celsis Model Identifies ROI in Advance

Frost & Sullivan cited the company's unique financial tool, the ValueCreation Model (VCM), as a key initiative driving Celsis' growth. Designed incollaboration with consulting firm Arthur D. Little, Inc., the VCM calculatesthe financial return from implementing the Celsis system for rapidmicrobiological testing. According to Celsis customer data, adopters of thesystem see an average return on investment in six to nine months with afive-year net present value (NPV) of $500,000 for a single plant. Thesestrong results, forecast by the VCM, encourage new customers to adopt thetechnology, and the tool has paved the way for Celsis to advance to the top ofthe market.

Additionally, as noted by Frost & Sullivan, the Celsis system is extremelyflexible, the workflow is easy to learn, and the instruments and software arestandardized, making it attractive to customers with multiple manufacturingfacilities or various types of products. Also attractive is the company'sactive research and development: Celsis is devising next-generation nucleicacid technologies to position itself for long-term growth.

For more information about the Celsis system, visithttp://www.celsis.com/rapid, where there is a link to a free whitepaper and anonline "lite" version of the Value Creation Model called the Rapid Returnscalculator. Frost & Sullivan Leadership Award information is available onlineat http://www.awards.frost.com.

About Celsis International plc

Celsis International plc is a leading international provider of innovativelife science products and laboratory services to the pharmaceutical andconsumer products industries. Each Celsis division delivers significant timeand cost savings to its customers in addition to ensuring product quality andsafety for consumers. Celsis' extensive client base includes many of theworld's leading pharmaceutical and consumer products companies. Public since1993, Celsis is headquartered in Chicago and listed on the London StockExchange (CEL.L).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients toaccelerate their growth. The company's TEAM Research, Growth Consulting andGrowth Team Membership empower clients to create a growth-focused culture thatgenerates, evaluates and implements effective growth strategies. Frost &Sullivan employs over 45 years of experience in partnering with Global 1000companies, emerging businesses and the investment community from more than 30offices on six continents. For more information about Frost & Sullivan'sGrowth Partnerships, visit http://www.awards.frost.com.

SOURCE Celsis International plc

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store